• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Estimates for the Central Nervous System Market Are Made for the Year 2005 and Projections Are Made to the Year 2010

Posted on: Tuesday, 13 December 2005, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c4511) has announced the addition of Jain PharmaBiotechs 'Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies' to their offering.

Who Should Read This Report

-- Marketing managers in CNS and drug delivery companies

-- R & D executives in companies developing CNS therapeutics

-- Venture capital and investment companies

-- Executives of major pharmaceutical companies with an interest in CNS

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.

Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB. Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance. It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Various routes of administration as well as conjugations of drugs, e.g., with liposomes and nanoparticles, are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery. Systemic therapy by oral and parenteral routes is considered along with sustained and controlled release to optimize the CNS action of drugs. Among the three main approaches to drug delivery to the CNS - systemic administration, injection into CSF pathways, and direct injection into the brain - the greatest developments is anticipated to occur in the area of targeted delivery by systemic administration.

Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.

The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.

The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Estimates are made for the year 2005 based on current markets and projections are made to the year 2010. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.

Special Features

-- Up to date. This report is updated at least once a month.

-- Compact. All the essential information on CNS drug delivery in 245 pages.

-- Comprehensive. Contains profiles of 55 companies in the field.

-- Complemented by 47 tables, 7 figures and 300 references.

-- Supported. The author is directly accessible to answer questions.

-- Best value. More information at a lower price than any comparable report.

-- Saves financial loss. Successful development and delivery of CNS drugs.

Contents Include:

Executive Summary

-- 1. Basics of Drug Delivery to the Central Nervous System

-- 2. Blood Brain Barrier

-- 3. Methods of Drug Delivery to the CNS

-- 4. Delivery of Cell, Gene and Antisense Therapies to the CNS

-- 5. Drug Delivery in the Treatment of CNS Disorders

-- 6. Markets for Drug Delivery in CNS Disorders

-- 7. Companies

-- 8. References

For more information visit http://www.researchandmarkets.com/reports/c4511.

Source: Business Wire

More News in this Category